Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-09-04
2008-09-09
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S319000
Reexamination Certificate
active
07423044
ABSTRACT:
This invention provides compounds of Formula I having the structure:wherein:B is alkyl of 1-4 carbons or alkoxy of 1-4 carbons;R1is aryl or Het optionally substituted with R6;R2and R3are each independently, alkyl of 1-4 carbons, CF3, aryl or Het substituted with R6, or R2and R3are combined to form a cycloalkyl or heterocyclic ring optionally substituted with alkyl, benzyl, or acyl;R4, and R5are each independently, hydrogen, halogen, alkyl of 1-4 carbons, CO2R7, SO2NHR7, CONHR7, CN, NO2or CF3;R6is hydrogen, halogen, NO2, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, alkylcarbonyloxy of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, CF3, or COOH; andR7is hydrogen, alkyl of 1-4 carbons, or alkylaryl where aryl group is substituted with R6; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
REFERENCES:
patent: 5298527 (1994-03-01), Grammenos et al.
patent: 6001867 (1999-12-01), Wrobel et al.
patent: 6699896 (2004-03-01), Malamas
patent: 6849761 (2005-02-01), Mayer et al.
patent: 4029649 (1992-03-01), None
patent: 4034672 (1992-05-01), None
patent: 0685467 (1995-12-01), None
patent: 1585950 (1981-03-01), None
patent: 04-001192 (1992-01-01), None
patent: 4-1192 (1992-06-01), None
patent: WO 94/14771 (1994-07-01), None
patent: WO 01/32632 (2001-05-01), None
Mitchell et al., CAPLUS Abstract 115:49608, 1991.
Reaven, et al., “Nonketotic Diabetes Mellitus: Insulin Deficiency or Insulin Resistance?”, American Journal of Medicine, (Jan. 1976), vol. 60, pp. 80-88.
Stout, Metabolism: Clinical & Experimental, (Dec. 1985), 34 (12 Suppl 1): 7-12, (Abstract).
Pyorala, et al., Diabetes/Metabolism Reviews, “Diabetes and Atherosclerosis: An Epidemiologic View”, (1987), vol. 3, pp. 463-524.
Jarrett, R. J., et al Diabetes/Metabolism Review, “Cardiovascular Disease and Hypertension in Diabetes Mellitus”, (1989), vol. 5, No. 7, 547-558.
Harris, et al., Diabetes in America, “Mortality From Diabetes”, Chapter 29, pp. 1-48, (1985).
Defronzo and Ferrannini, Diabetes Care, “Insulin resistance.”,(Mar. 1991), 14, 173-194 (Abstract).
Haring, Diabetalogia, “The insulin receptor: signalling mechanism and contribution to the pathogenesis of insulin resistance”, (1991), 34, 848-861 (Abstract).
B.J. Goldstein, J. Cellular Biochemistry, “Protein-tyrosine phosphatases and the regulation of insulin action”, (1992), 48, 33 (Abstract).
B.J. Goldstein, Receptor , “Reg. of insulin receptor signaling by protein-tyrosine dephosphorylation”, (1993), 3, 1-15 (Abstract).
F. Ahmad and B.J. Goldstein Biochim. Biophys Acta , “Purification, identification and subcellular distribution of three predominant protein-tyrosine phosphatase enzymes in skeletal muscle tissue”, (1995), 1248, 57-69 (Abstract).
McGuire, et al., Diabetes, “Abnormal Regulation of Protein Tyrosine Phosphatase Activities in Skeletal Muscle of Insulin-Resistant Humans”, (1991), vol. 40, 939-942.
Meyerovitch, et al., J. Clinical Invest., “Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats”, (1989), vol. 84, 976-983 (Abstract).
Sredy, et al Metabolism: Clinical & Experimental, “Insulin resistance is associated with abnormal dephosphorylation of a synthetic phosphopeptide corresponding to the major autophosphorylation sites of the insulin receptor”, 44, 1074-1081 1995 (Abstract).
Thomson Derwent on STN Abstract—Patent No. JP-04001192 A, Appl. 190JP-0100824, Apr. 17, 1990.
Thomson Derwent on STN Abstract—Patent No. DE-4034762A, Appl. 199DE-4034762, Nov. 2, 1990.
Goldstein, Barry. “Hot Topic: Protein-Tyrosine Phosphatases: Emerging Targets for Therapeutic Intervention in Type 2 Diabetes and Related States of Insulin Resistance.” Journal of Clinical Engineering & Metabolism, 87(6), 2474-2480, 2002.
Lie, Gang et al. “Discovery and Structure-Activity Relationship of Oxalylarylaminobenzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B.” J. Med. Chem. 46, 2093-2103, 2003.
Cosford, Robyn. “Insulin Resistance, Obesity and Diabetes: The Connection.” Journal of the Australian College of Nutritional and Environmental Medicine. 18:1, 3-10, Apr. 1999.
Fish & Richardson P.C.
Rao Deepak
Wyeth
LandOfFree
Pyrimidine derivatives useful in the treatment of insulin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine derivatives useful in the treatment of insulin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine derivatives useful in the treatment of insulin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3971930